Labcorp Holdings Posts Q3 Revenue of $3.81B and Raises Full-Year Adjusted EPS Guidance to $18.30-$18.70

Labcorp Holdings reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from $3.56 billion in the year-ago period, beating analyst estimates by roughly $50 million. Adjusted EPS came in at $4.78, topping consensus by $0.13 to $0.14, while GAAP diluted EPS rose to $3.22 from $3.12 a year earlier. Net income for the quarter was $262.8 million, with operating income of $402.1 million and cash flow from operations of $563.8 million. CEO Adam Schechter cited 7% revenue growth, continued margin expansion, and 14.5% adjusted EPS growth as the drivers behind the results.

Building on the beat, Labcorp raised its full-year 2026 guidance across key metrics. The updated adjusted EPS range is $18.30 to $18.70, up from the prior range of $18.10 to $18.55. Full-year enterprise revenue guidance was set at $14.779 billion to $14.887 billion, implying growth of 5.9% to 6.7%, with Diagnostics Laboratory revenue guided to $11.475 billion to $11.551 billion. Free cash flow guidance was held steady at $1.24 billion to $1.36 billion. The company also highlighted specialty testing expansion, including new tests for advanced melanoma, Alzheimer's disease, and hepatitis D, alongside strategic acquisitions in both its Diagnostics and Biopharma Laboratory Services segments.

Shares responded sharply, touching an all-time high of $343.13 on October 28 and outperforming peers on a strong trading day. The Benzinga report noted that Labcorp is targeting continued margin growth while absorbing policy headwinds, positioning the company to benefit from trends in personalized medicine and evolving healthcare technology.